Search clinical trials for: Vericiguat (BAY1021189) (5 mg)

Total 1183 results

Bayer

Completed

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)

Heart Failure

Belgium, France, Switzerland, United States, Spain, Greece, Japan, Singapore, Austria, Germany, Korea, Republic of, Poland, Denmark, Israel, Netherlands, Taiwan, Bulgaria, Canada, Sweden, Czechia, Australia, Italy, Hungary, United Kingdom
Bayer

Completed

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)

Heart Failure

Belgium, France, Spain, Greece, Portugal, Japan, United States, Singapore, Austria, Germany, Korea, Republic of, Poland, Australia, Israel, Netherlands, Switzerland, Taiwan, Bulgaria, Canada, Czechia, Denmark, Hungary, Italy, Sweden, United...
Bayer
Merck Sharp & Dohme LLC

Recruiting

A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Chronic Heart Failure With Reduced Ejection Fraction

Spain, United States, Argentina, Hungary, Italy, Poland, Sweden
Bayer
Merck Sharp & Dohme LLC; Duke Clinical Research Institute; Canadian VIGOUR Centre

Completed

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF (VITALITY-HFpEF)

Chronic Heart Failure With Preserved Ejection Fraction

Spain, United States, Belgium, Singapore, Taiwan, Canada, Japan, Italy, Austria, Bulgaria, Germany, Greece, Israel, Poland, Portugal, Hungary, Russian Federation, Argentina, Colombia, Malaysia, South Africa
Bayer
Merck Sharp & Dohme LLC

Completed

A Study in Healthy Adult Male Participants to Learn the Way Vericiguat is Absorbed With and Without Food When Taken as a Single Dose in Liquid Form Suitable for Children Compared to a 10 Milligram (mg) Tablet That Releases the Active Substance Immediately

Heart Failure | Children

Germany
Bayer

Completed

Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects

Pharmacokinetics

Germany
Bayer

Active, not recruiting

An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States (HOVER)

Chronic Heart Failure With Reduced Ejection Fraction

United States
Bayer

Recruiting

An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting

Chronic Heart Failure With Reduced Ejection Fraction

Korea, Republic of
Bayer

Recruiting

A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction)

Chronic Heart Failure With Reduced Ejection Fraction | Worsening Heart Failure

India
Bayer

Recruiting

A Study to Learn More About the Safety of the Drug Vericiguat in Japanese People With Chronic Heart Failure Who Will be Receiving Vericiguat Under Real-world Conditions

Chronic Heart Failure

Japan
Bayer
Merck Sharp & Dohme LLC

Completed

A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Liver Disease and in Age-, Weight- and Gender-matched Healthy Participants

Heart Failure

Germany
Bayer

Recruiting

An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China (VERI-China)

Chronic Heart Failure With Reduced Ejection Fraction

China
Bayer
Merck Sharp & Dohme LLC

Completed

Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients (VENICE)

Coronary Artery Disease

Germany
Bayer
Merck Sharp & Dohme LLC

Completed

A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Kidney Disease and in Age-, Weight- and Gender-matched Healthy Participants

Heart Failure

Germany
Bayer
Merck Sharp & Dohme LLC

Completed

Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients (VISOR)

Coronary Artery Disease

Germany
Bayer
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat

Coronary Artery Disease

Germany, Moldova, Republic of, Netherlands
Pfizer

Completed

Multiple Oral Doses Of PH-797804 In Healthy Japanese Adult Subjects

Healthy

United States
Anesiva, Inc.

Completed

Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee Replacement

Total Knee Arthroplasty (Replacement)

United States
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects

Type II Diabetes
GlaxoSmithKline

Terminated

Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal Impairment

Anaemia

United States
Janssen Research & Development, LLC

Terminated

An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia (EARLY)

Asymptomatic Amyloid-positive

United States, Canada, United Kingdom, Belgium, Germany, Spain, Japan, Australia, Netherlands, Denmark, Mexico, Finland, Sweden
Suzhou Kintor Pharmaceutical Inc,

Completed

Phase II Study Evaluating the Efficacy and Safety of KX-826

Androgenetic Alopecia (AGA)

China
Proteimax Biotechnology Israel LTD

Recruiting

Effect of Consumption of Pep19 on Quality of Life

Quality of Life | Obesity | Sleep Quality

United States
Edgewise Therapeutics, Inc.
Medpace, Inc.; SYSNAV; ImagingNMD

Recruiting

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

Becker Muscular Dystrophy

United States, Netherlands, United Kingdom
GSNOR Therapeutics, Inc.

Unknown

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)
Laboratorios Andromaco S.A.

Completed

Bioavailability of Clotiazepam 5 mg With Regards to Reference Product

Bioequivalence

Chile
Estetra

Completed

Safety, Tolerability and Pharmacokinetics of Estetrol (E4) After Single and Multiple Oral Doses in Healthy Female Volunteers

Menopause | Contraception

Bulgaria
Gannex Pharma Co., Ltd.

Completed

Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

China
Daiichi Sankyo, Inc.

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

Atopic Dermatitis

United States
AstraZeneca

Completed

Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects

Reflux

Netherlands, Belgium
Taisho Pharmaceutical Co., Ltd.

Completed

A Pharmacokinetic Study of TS-142 in Patients With Hepatic Impairment

Patients With Mild or Moderate Hepatic Impairment

Japan
University of Alabama at Birmingham

Not yet recruiting

VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway (VITAL-IMPACT)

Cardiovascular Diseases | Obesity | Insulin Sensitivity/Resistance | Metabolic Disease | Energy Expenditure | Metabolism

United States
Taisho Pharmaceutical Co., Ltd.

Completed

Long-Term Study of TS-142 in Patients With Insomnia

Patients With Insomnia

Japan
Ferring Pharmaceuticals

Terminated

26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation

Chronic Idiopathic Constipation

Israel, Belgium, United States, United Kingdom, Germany, Poland, Brazil, Canada, Czech Republic, South Africa
PHARMENTERPRISES LLC

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of Treamid in Healthy Volunteers

Metabolic Syndrome
Boryung Pharmaceutical Co., Ltd

Withdrawn

A Study to Compare the Pharmacokinetics and Safety/Tolerability of BR-UPS (Ulipristal Acetate) 5 mg Tablet With Inisia (Ulipristal Acetate) 5 mg Tablet

Uterine Myoma

Korea, Republic of
Pfizer

Terminated

An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia

Schizophrenia

United States
Kyowa Kirin Co., Ltd.

Completed

A Study of OPC-262 in Patients With Type 2 Diabetes

Diabetes Type 2

Japan
University of Pennsylvania
National Heart, Lung, and Blood Institute (NHLBI); National Institute of Arthritis... and other collaborators

Active, not recruiting

The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach (TAPIR)

Granulomatosis With Polyangiitis

United States, Canada
Actinogen Medical
Avance Clinical

Completed

A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers (XanaMIA-DR)

Mild Cognitive Impairment | Alzheimer's Disease

Australia
Suzhou Kintor Pharmaceutical Inc,
Suzhou Koshine Biomedica, Inc.

Active, not recruiting

Phase III Study of KX-826 With Adult Male Patients With AGA

Androgenetic Alopecia

China
Cytokinetics

Enrolling by invitation

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM (FOREST-HCM)

Symptomatic Hypertrophic Cardiomyopathy (HCM)

United States, France, Israel, Spain, United Kingdom, Italy, Portugal, Poland, Hungary, Denmark, Netherlands, Germany, Czechia
Pfizer

Withdrawn

A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease

Dementia | Alzheimer's Disease | Dimebon | Investigational Drug
Conatus Pharmaceuticals Inc.

Completed

Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis (ENCORE-NF)

Liver Diseases | Fibrosis | Non-alcoholic Steatohepatitis

United States, Spain, Germany
AstraZeneca
Parexel

Completed

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Type 2 Diabetes Mellitus

United States
Janssen Research & Development, LLC

Terminated

An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum

Alzheimer Disease

France, Spain, Netherlands, Belgium, Germany, Sweden
Eisai Co., Ltd.

Completed

A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Alzheimer's Disease

Japan
Pfizer

Terminated

A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.

Healthy

Singapore
Boehringer Ingelheim

Completed

Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM

Diabetes Mellitus, Type 2

United States, Argentina, Austria, Belgium, Canada, China, Croatia, Czech Republic, Finland, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, R... and more
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants

Healthy

Japan

3

Subscribe